Crit Care 2009,13(3):R99.PubMedCrossRef ACY-1215 price 247. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F: Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010,14(4):R126. Epub 2010 Jul 1PubMedCrossRef 248. Pea F, Viale P: Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock–does the dose matter? Crit Care 2009,13(3):214.PubMedCrossRef 249. Mueller EW, Boucher BA: The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered
in critically ill surgical patients. Surg Infect 2009,10(6):563–570.CrossRef
250. Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML: Clinicalcure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009,33(5):464–468.PubMedCrossRef 251. Roberts JA, Lipman J, Blot S, Rello J: Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 2008,14(4):390–396.PubMedCrossRef 252. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Cantón R, Baquero F: Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases Smoothened Agonist mw in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 study for
monitoring antimicrobial resistance trends (SMART). Antimicrob Agents Chemother 2010,54(7):3043–3046.PubMedCrossRef SPTLC1 253. Ben-Ami R, Rodriguez-Bano J, Arsian H, Pitout JD, Quentin C, Calbo ES, Azap OK, Arpin C, Pascual A, Livermore DM, Garau J, Carmeli Y: A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009, 49:682–690.PubMedCrossRef 254. Nordmann P, Cuzon G, Naas T: The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009,9(4):228–236.PubMedCrossRef 255. Patel N, Harrington S, Dihmess A, Woo B, Masoud R, Martis P, Fiorenza M, Graffunder E, Evans A, McNutt LA, Lodise TP: Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J Antimicrob Chemother 2011,66(7):1600–1608.PubMedCrossRef 256. Ho J, Tambyah PA, Paterson DL: Tariquidar in vitro Multiresistant gram-negative infections: a global perspective. Curr Opin Infect Dis 2010,23(6):546–553.PubMedCrossRef 257. Lin WJ, Lo WT, Chu CC, Chu ML, Wang CC: Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infection in children. J Microbiol Immunol Infect 2006, 39:249–254.PubMed 258.